Jun 02, 2020
Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative Drugs
Jun 01, 2020
Alligator Bioscience's Collaboration With Biotheus Inc. Proceeds and Second Payment is Received
Jun 01, 2020
Society for Immunotherapy of Cancer Celebrates Cancer Immunotherapy Month(TM)
May 29, 2020
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
May 29, 2020
Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity
May 29, 2020
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
May 29, 2020
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
May 29, 2020
Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020
May 29, 2020
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
May 29, 2020
Amphivena Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 29, 2020
PathAI Demonstrates the Potential of AI-based Characterization of the Tumor Microenvironment at ASCO
May 28, 2020
Clinical Studies & Research Progressing for Finding Cure for Glioblastoma
May 28, 2020
LabRoots Unveils Inaugural, Immuno-Oncology Focused Online Conference, Scheduled on June 3rd
May 27, 2020
Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
May 27, 2020
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
May 27, 2020
Blueprint Medicines to Present at Upcoming Investors Conferences
May 26, 2020
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
May 22, 2020
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
May 21, 2020
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7(TM) in Glioblastoma Multiforme
May 18, 2020
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II